The prototypic long pentraxin 3 (PTX3) is a fluid phase pattern recognition receptor which plays non-redundant roles in the resistance against diverse pathogens, in the assembly of a hyaluronic acid-rich extracellular matrix and in female fertility. Inflammatory signals induce production of PTX3 in diverse cell types including myeloid dendritic cells (DC), fibroblasts and endothelial cells (EC). The present study was designed to explore the effect of glucocorticoid hormones (GC) on PTX3 production in different cellular contexts. In myeloid DC GC inhibited the PTX3 production. In contrast, in fibroblasts and EC GC alone induced and, under inflammatory conditions, enhanced and extended PTX3 production. In vivo administration of GC augmented the blood levels of PTX3 in mice and humans. Moreover, patients with Cushing's syndrome had increased levels of circulating PTX3 whereas PTX3 levels were decreased in subjects affected by iatrogenic hypocortisolism. In non-hematopoietic cells, GC receptor (GR) functioned as a liganddependent transcription factor (dimerizationdependent) to induce PTX3 gene expression. In contrast, in hematopoietic cells, GR repressed PTX3 gene transcription by interfering (dimerization-independent) with the action of other signalling pathways, likely NFκB and AP-1. Thus, divergent effects of GC were found to be due to different GR mechanisms. The results presented here indicate that GC have divergent effects on PTX3 production in hematopoietic (DC and macrophages) and non-hematopoietic (fibroblasts and EC) cells. The divergent effects of GC on PTX3 production is likely to reflect the different functions of this multifunctional molecule in innate immunity and in the construction of the extracellular matrix.
The prototypic long pentraxin 3 (PTX3) is a fluid phase pattern recognition receptor which plays non-redundant roles in the resistance against diverse pathogens, in the assembly of a hyaluronic acid-rich extracellular matrix and in female fertility. Inflammatory signals induce production of PTX3 in diverse cell types including myeloid dendritic cells (DC), fibroblasts and endothelial cells (EC). The present study was designed to explore the effect of glucocorticoid hormones (GC) on PTX3 production in different cellular contexts. In myeloid DC GC inhibited the PTX3 production. In contrast, in fibroblasts and EC GC alone induced and, under inflammatory conditions, enhanced and extended PTX3 production. In vivo administration of GC augmented the blood levels of PTX3 in mice and humans. Moreover, patients with Cushing's syndrome had increased levels of circulating PTX3 whereas PTX3 levels were decreased in subjects affected by iatrogenic hypocortisolism. In non-hematopoietic cells, GC receptor (GR) functioned as a liganddependent transcription factor (dimerizationdependent) to induce PTX3 gene expression. In contrast, in hematopoietic cells, GR repressed PTX3 gene transcription by interfering (dimerization-independent) with the action of other signalling pathways, likely NFκB and AP-1. Thus, divergent effects of GC were found to be due to different GR mechanisms. The results presented here indicate that GC have divergent effects on PTX3 production in hematopoietic (DC and macrophages) and non-hematopoietic (fibroblasts and EC) cells. The divergent effects of GC on PTX3 production is likely to reflect the different functions of this multifunctional molecule in innate immunity and in the construction of the extracellular matrix.
Pentraxins are a superfamily of conserved proteins usually characterized by a cyclic multimeric structure (1) (2) (3) (4) . The classic short pentraxins C-reactive protein (CRP) and serum amyloid P component (SAP) are acute phase proteins in man and mouse, respectively. They are produced in the liver in response to inflammatory signals, most prominently IL-6. CRP and SAP bind different ligands, in a calcium dependent manner, and they are involved in the innate resistance to microbes and the scavenging of cellular debris and extracellular matrix components (5) .
The prototypic long pentraxin PTX3 shares similarities with the classical short pentraxins. However it has an unrelated long Nterminal domain coupled to the C-terminal pentraxin domain, and differs in gene organization, cellular source, inducing stimuli and ligands recognized (3, 4, 6) . PTX3 is rapidly produced and released by several cell types, in particular by mononuclear phagocytes, myeloid DC, fibroblasts, epithelial and EC in response to primary inflammatory signals (e.g. TLR engagment, TNFα, IL-1β) (3, (7) (8) (9) (10) (11) and its production is amplified by . PTX3 binds the complement component C1q, apoptotic cells, the extracellular matrix component TSG6 and selected microorganisms, including Aspergillus fumigatus and Pseudomonas aeruginosa (13) (14) (15) (16) (17) (18) (19) .
Recent studies in gene-modified mice have shown that PTX3 plays complex nonredundant functions in vivo, ranging from innate immunity against diverse microorganisms to the assembly of a hyaluronic acid-rich extracellular matrix and female fertility (3, 6, 14, 16, 17, (20) (21) (22) . PTX3 acts as a fluid phase pattern recognition receptor which plays a non-redundant role in resistance against selected pathogens and has properties similar to antibodies. Its production is induced by pathogen recognition, it recognizes microbial moieties, activates the classical pathway of complement and facilitates recognition by macrophages and DC. Thus, PTX3 behaves as a bona fide ante-antibody (3, 6, 14, 17, 18) .
PTX3 is also a constituent of the extracellular matrix which plays a nonredundant role in the assembly of the hyaluronan-rich viscoelastic matrix of the cumulus oophorus and hence in female fertility (3, 6, 14, 16, 21, 23) . PTX3 binds TSG6, a hyaluronic acid-binding protein and may act as a focal point of the assembly of hyaluronic acidrich matrices (3, 6, 16) .
In addition, PTX3 has a tuning function under inflammatory conditions at least in part limiting tissue damage by regulating apoptotic cell clearance and acting as a third-party agent between microbial stimuli and dying cells (3, 19, 22, (24) (25) (26) (27) .
GC have a complex regulatory activity on components of innate and adaptive immunity (28) (29) (30) . As PTX3 is a multifunctional fluid phase pattern recognition receptor which links innate immunity, inflammation and matrix deposition, and shows a unique pattern of regulation (3, 12) , we explored the GC effect on the PTX3 production. The present study reports that exogenous, as well as endogenous GC, regulate PTX3 production in a cell-type specific manner and through different actions of GR. The divergent effect of GC on PTX3 production in hematopoietic (DC and macrophages) and nonhematopoietic (fibroblasts and EC) cells mirrors the diverse functions of this molecule in innate immunity and in the assembly of the extracellular matrix.
EXPERIMENTAL PROCEDURES

Media and reagents
The following reagents were used for tissue culture: pyrogen-free saline (S. A. L., Bergamo, Italy), RPMI 1640 medium (Biochrom, Berlin, Germany), M199 medium (Biochrom, Berlin, Germany), 200mM L-glutamine (Biochrom, Berlin, Germany), aseptically collected fetal calf serum (FCS) (Hyclone, Laboratories, Logan, UT) and PBS (Cambrex Bio Science, Belgium). Heparin and collagenase were from SIGMAAldrich. Human recombinant granulocyte macrophage colony-stimulation factor (GM-CSF) was a gift from Novartis (Milan, Italy) and human IL-13 was a gift from A. Minty (Sanofi Elf Bio Recherches, Labège, France). Recombinant TNFα and IL-1β were purchased by Peprotech (London, GB) and LPS from E. Coli serotype R515 (RE) (>99.9% of purity) was obtained from Alexis. Diverse Dex (Dexamethasone-21-phosphate disodium salt) preparations from MP Biomedicals (Germany) and Sigma-Aldrich were used. RU486 (Mifepristone) and PGE 2 were obtained from SIGMA-Aldrich. Vitamin D 3 (VitD 3 ) was a gift from Luciano Adorini (Bioxell, Milan, Italy). Reagents were controlled to exclude endotoxin contamintion by LAL test (BioWhittaker Inc.-Cambrex, MD).
DC and Macrophages
Monocyte-derived DC were generated as previously described (8 (10) which spans nucleotides 1 to 1374 of human PTX3 promoter (accession X97748) was used as DNA template for polymerase chain reaction (PCR) with the following oligonucleotides: Forward primer (5'-AAAAAGGTACCCCGGATCTCCCTTCTAA C-3') was designed in antisense orientation on PTX3 promoter from nucleotide 7 to nucleotide 25 with an additional 11 nucleotides at the 5' end; 6 of them (underlined) give rise to a KpnI restriction site; Revers primer (5'-TTTCCACAGCTGGCGGGAGGAGACTCTC AA -3') was designed in sense orientation on the PTX3 promoter from nucleotides 1351 to 1380, it includes (underlined) a PvuII site. The PCR reaction products were subcloned in pGEMT easy vector, next human PTX3 promoter fragment was excised by KpnI-PvuII digestion and subcloned in SmaI-KpnI digested pGV-B2 vector. The luciferase reporter clones containing the human PTX3 promoter were sequenced (Primm) and subsequently used in functional assays. Cells transfections were performed using lipofectamine 2000TM according to the manufacturer's instructions (Invitrogen, Life Technologies). Luciferase assay was performed using the Luciferase Assay Kit by Promega (Cat. # E1500). Briefly, cells were stimulated at various times as described, washed in PBS and resuspended in Cell Lysis Buffer (Promega Kit). Cell Lysate proteins were quantified using Comassie method (Biorad). In order to perform luciferase assay, 50 μL of luciferase substrate, reconstituted following the manufacturer's instructions, were added to 15µg of total proteins. Signals was read on Luminometer LB 9507 (Berthold Inc.) RNA For Northern Blot analysis total RNA was extracted by TRIzol method in according to manufacturer's instructions (Invitrogen, Life Technologies), blotted and hybridized as described (8) . PTX3 mRNA densitometric analysis was performed by quantification of relative optical density (ROD) x area using an Image Analysis Software (AIS) (Image Research, Inc., Ontario). For gene expression analysis by quantitative PCR, according to the manufacturer's instructions, total RNA was reverse transcribed using cDNA Archive kit (Applied Biosystem, NJ, USA), then real time PCR was performed with Power Syber Green PCR Master Mix (Applied Biosystem) and detected by 7900HT Fast Realtime System (Applied Biosystem). Data was processed using the SDS2.2.2 software (Applied Biosystem). All results were normalized to the expression of the housekeeping gene, β-actin, in the PCR reactions and expressed as folds change in mRNA expression with respect to the untreated cells. Data represented are from 3 independent experiments done in triplicate.
Chromatin Immunoprecipitation Assay (ChIP)
ChIP assays were performed in HUVEC, WI38 and DC as previously described (34) . Chromatin was sheared by sonication to give fragments 500-1000bp length. Chromatin immunoprecipitation was performed overnight at 4°C with 4µg of a rabbit polyclonal anti-RNA Pol II antibody (N-20, #B0408), a rabbit polyclonal anti-GR (H-300, #B0604) and a control antisera (Santa Cruz Biotechnologies, CA). Immunoprecipitated DNA was amplified by Real-time PCR with PTX3 promoter-specific primers spanning PTX3 promoter from nucleotide 1231 to nucleotide 1380. The ChIP results were normalized to input and expressed as fold induction with respect to the control cells. Data are 3 independent experiments representative done in triplicate. Proteins Human PTX3 (PTX3) was measured using an ELISA previously described (35) . IL-6 was measured by ELISA in according to manufacturer's instructions (R&D Systems, Minneapolis, MN). Murine PTX3 (mPTX3) was measured by ELISA based on mAbs obtained by immunization of PTX3 -/ -mice (14) . In brief, 96-well ELISA plates (Nunc, Roskilde, Denmark) were coated with 100ng of anti-mPTX3 monoclonal antibody (mAb) MnmE1. Nonspecific binding sites were saturated by 300µl of 5% dry milk, prior to the addition of purified recombinant mPTX3 standards (from 0.1 to 10ng/mL) and unknown samples, diluted in PBS (Cambrex Bio Science, Belgium) plus 2% of bovine serum albumin BSA (SIGMA-Aldrich). After incubation, 25ng of biotin-conjugated antimPTX3 mAb MNmE2 were added. Streptavidin-peroxidase was then added followed by the addition of TMB liquid Substrate System (SIGMA-Aldrich). After each step, plates were extensively washed with PBS (Cambrex Bio Science, Belgium) containing 0.05% Tween 20 (Merk, Germany), also used for reagent diluent. Immunohistochemistry Skin samples (1 normal and 1 with Cushing syndrome) were collected and fixed in 4% formalin. Paraffin embedded tissue were cut at 4 μm, and incubated with 2% H 2 O 2 in methanol (to eliminate endogenous peroxidase activity). Sections were pre-incubated with PBS + 1% BSA + 1% normal human serum + 0.02% NP40 (SIGMA-Aldrich) to block non specific sites for 10 minutes at room temperature and than incubated at room temperature for 2 hours with an anti-PTX3 affinity-purified rabbit polyclonal (0.25µg/mL). A purified rabbit serum was also used as negative control. After extensive wash sections were incubated with secondary antibodies, Super Sensitive IHC Detection Systems (BioGenex, San Ramon, USA) was used according to the manufacturer's instructions. Staining reactions were performed with 3,3-diaminobenzidine (DAB, BioGenex) as substrate. Sections were counterstained with hematoxylin and mounted with Eukitt. Mice PTX3 levels were measured in male, adult (8 weeks), C57/BL6 mice (Charles River Lab., Calco, Italy). Dex was prepared as a suspension in PBS (Cambrex Bio Science, Belgium) at 5mg/mL and was administrated, at 30mg/Kg, via i. p. injection prior to blood collection at 24h. Control mice received i. p. injections of vehicle. Six animals were examined for each experimental group. Patients The study included 16 patients with hypercortisolism and 8 patients with hypocortisolism admitted to the Endocrine Unit, Fondazione Policlinico, IRCCS. All patients with hypercortisolism (5 males and 11 females, aged 34 to 72) were affected by ACTHdependent Cushing syndrome due to either a pituitary adenoma or to ectopic ACTH syndrome. All patients had elevated 24h urinary cortisol excretion and lack of suppression of cortisol levels after low dose Dex test. Patients with hypocortisolism (4 males and 5 females, aged 40 to 67) had a history of Cushing disease due to a pituitary adenoma surgically removed by the transsphenoidal route. Three months after surgery, all patients had reduced 24h urinary cortisol excretion and lack of induction of cortisol levels after a low dose (1μg) ACTH stimulation test. The patients were evaluated after adequate cortisone acetate treatment withdrawal. Serum PTX3 and cortisol levels were measured in 7 normal subjects, both under basal conditions and after an overnight treatment with 1 mg Dex. PTX3 was measured by ELISA as described. Serum cortisol levels were measured by EIA method (Nichols Institute, San Juan Capistrano, USA). The control cohort was from the same unit. Informed consent was obtained in all cases, after project approval by the local Ethic Committee.
RESULTS
Regulation of PTX3 production by GC in monocyte-derived DC
In a first series of experiments, we evaluated the effect of GC on monocyte-derived DC and their capability to regulate the PTX3 production. M) and combinations thereof. As expected, LPS induced PTX3 production in DC (8) and resulted in release of 14.8 ± 6.7ng/mL and 42.7 ± 12.0 ng/mL (mean ± SD) when DC were challenged for 24h with either 1 or 100ng/mL of LPS respectively. GC alone did not induce PTX3 in DC. In all experiments performed, Dex caused a strong inhibition of the LPS-induced PTX3 production. As shown in Figure 1 Panel A, when Dex (10 -5 M) was combined to either 1 or 100ng/mL LPS, the inhibition of PTX3 production was 63.0 ± 14.5% or 59.5 ± 12.0%, respectively. The inhibitory effect of GC on PTX3 production by monocytederived DC was dose-related (range of 10 When RU486 (mifepristone), a GR antagonist, was combined to LPS and Dex, the regulatory effect of GC on PTX3 production by myeloid DC was blocked. As shown in Figure 1 Panel B, in a series of 4 experiments, PTX3 production induced by LPS (61.1 ± 4.2ng/mL) was inhibited by the addition of Dex (37.0 ± 3.4ng/mL), but not when RU486 was added to the culture (57.1 ± 12.1ng/mL). RU486 did not induce PTX3 and did not alter the LPS-induced PTX3 production by DC (65.1 ± 13.2ng/mL) (Figure 1 Panel B) .
Thus, the inhibitory effect of Dex on LPSinduced PTX3 production by myeloid DC is GR-dependent. PTX3 transcript levels were assessed by Northern Blot analysis and, as shown in Figure  1 M, caused an inhibition of transcript levels corresponding to 64% or 59% of the response to LPS, respectively. GC also inhibited the PTX3 production by LPStreated monocytes and macrophages (data not shown).
Regulation of PTX3 production by GC in nonhematopoietic cells
As PTX3 is produced by several cell types, including fibroblasts and EC (3), we evaluated also the ability of GC to regulate the PTX3 production in a human fibrosarcoma (8387), normal human fibroblasts (WI38) and HUVEC. In all experiments performed (n = 4), unexpectedly Dex alone induced production of PTX3 in 8387 cells (52.9 ± 1.1ng/mL) after 24h of culture (Figure 2 Panel A, left part). PTX3 induction was observed following challenge with IL-1β (31.5 ± 1.0ng/mL) and TNFα (46.9 ± 0.8ng/mL). When Dex was combined with IL-1β or TNFα, an additive or synergistic enhancement of PTX3 production was observed in 8387 (142.7 ± 3.9%, 78.9 ± 9.1%) (Figure 2 
Panel A).
As expected, the TNFα-induced IL-6 was significantly down-regulated by GC both in myeloid DC (data not shown) and in 8387 (series of 3 experiments, Figure 2 Panel A, right part). It was important to ascertain whether the production of PTX3 by GC in cells of fibroblastic origin was receptor-dependent. In a series of 3 experiments (Figure 2 Panel B), PTX3 production by GC-stimulated 8387 (42.0 ± 7.1ng/mL) was significantly inhibited when cells were cultured in the presence of RU486 (26.1 ± 1.6ng/mL, p < 0.05). As expected, TNFα-induced PTX3 production (93.1 ± 5.4ng/mL) by 8387 was markedly augmented in combination with Dex (132.8 ± 15.0ng/mL). The augmentation by Dex was inhibited by the addition of RU486 (86.0 ± 14.6ng/mL). RU486 did not inhibit the TNFα-induced PTX3 production (88.4 ± 7.6ng/mL) (Figure 2 Panel B). Thus, RU486 blocked the effects of GC on PTX3 production both in fibroblasts and in DC. Similar results were obtained when the WI38 normal fibroblast cell line was used (4 experiments performed, a representative shown in Figure 3 Panel A and Panel B). EC are a major source of PTX3 (3). Dex induced PTX3 production in HUVEC (19.7 ± 1.7ng/mL, in the experiment shown in Figure 4 Panel A, representative of 4 performed), although less efficiently than IL-1β (28.7 ± 6.2ng/mL). Dex superinduced PTX3 in combination with IL-1β, corresponding to 164.7 ± 11.2% of the IL-1β response (63.3 ± 5.2ng/mL) (Figure 4 Panel A). RU486 completely blocked the production of PTX3 by Dex but did not alter the IL-1β-induced PTX3 production (Figure 4 Panel B). The effect of GC on PTX3 production by 8387 fibroblasts was dose-related (10 C) . VitD 3 and PGE2, which inhibit the LPS-induced PTX3 production in myeloid DC (12), did not induce and did not alter PTX3 production in HUVEC ( Figure 5 ) and in fibroblasts (data not shown). Stimulation with different hormones (e. g. T3 and T4), which, as GC, engage receptors belonging to superfamily of nuclear receptors, did not affect PTX3 production by DC and fibroblasts (data not shown). The time course of PTX3 production in nonhematopoietic cells was different in response to TNFα and GC ( Figure 6 , 3 experiments performed). PTX3 induction in response to TNFα was already evident after 8h whereas induction by GC required 16h. GC-induced PTX3 production was sustained up to 48h. Sustained production over time was also observed when TNFα and GC were combined ( Figure 6 ). GC were found to induce PTX3 mRNA and to enhance the induction by TNFα and IL-1β in fibroblasts and EC (range of 5h-10h). Addition of RU486 inhibited the GR-mediated augmentation of PTX3 expression (Figure 7) . Mechanism of PTX3 regulation by GC It was important to explore the molecular mechanism of the divergent PTX3 regulation by GC. PTX3 promoter was found to contain binding sites for the transcription factors NFκB and AP-1, which confer responsiveness to IL-1β, LPS and TNFα (36, 37) . We investigated whether GC directly modulate the PTX3 gene expression. The analysis of human PTX3 gene promoter (GenBank accession no. X97748) by Signal Scan software (38) allowed us to identify putative GR responsive regions. Thus, to evaluate GC regulation of PTX3 gene expression in both fibroblasts and macrophages, a reporter plasmid (pGV-B2) carrying human PTX3 promoter linked to luciferase gene was generated and used to transiently transfect RAW 264.7 and 8387 cell lines. Therefore we evaluated the transcriptional regulation of the PTX3 promoter by GC in fibroblasts and macrophages. In RAW 264.7 cell line PTX3 promoter activity significantly increased (3.2-fold, p = 0.009) following a 16h challenge with LPS (10ng/mL) compared to untreated cells. Treatment with Dex (10 -6 M) counteracted (-1.79-fold, p = 0.039) the transcriptional activation of PTX3 promoter induced by LPS (a representative experiment of 3 performed is shown in Figure 8 Panel A). In RAW 264.7 cells Dex did not induce PTX3 promoter activity. The GC-mediated PTX3 gene repression was also observed when cells were also treated for 4 and 8h (not shown). Figure S3 , for the two experiments not shown). The PTX3 promoter responded to both TNFα (1.73-fold, p = 0.003) and Dex (1.72-fold, p = 0.013) used alone, and its activity was further enhanced following a combined treatment (2.34-fold, p = 0.017). The luciferase activity induced by GC was repressed when cells were incubated in the presence of the antagonist RU486 (Figure 8 Panel B). Similar results were obtained at 4h and 8h (data not shown).
Following binding to the GR, GC exert diverse regulatory activities through complex mechanisms. The GR either directly engages GC response elements (GRE) in the regulatory regions of genes, or indirectly, via interactions with other transcription factors (30, 39) . GR dimerization deficient (GR dim/dim ) mice provide a tool to differ the mechanism of action of GC, in which GRE-mediated gene activation, which is entirely dependent on GR dimerization, is removed but GR interactions with NFκB and AP-1, which are independent of dimerization, are still possible (32) . Therefore, we ascertained the effect of GC on PTX3 expression in bone marrow-derived macrophages (BMM) and MEF from WT or GR dim/dim mice. First, we employed a quantitative PCR to explore the changes in regulation of LPSinduced expression of PTX3 mRNA in BMM from WT and GR dim/dim mice. RNA from macrophages was collected following treatment with LPS (10ng/mL), Dex (10 -6 M) or LPS plus Dex for different times. One representative experiment at 8h out of three performed is shown in Figure 9 Panel A and the other two are presented in Supplemental Data Figure S4 . Dex alone was able to appreciably modify the steady state levels of PTX3 mRNA in macrophages from WT and GR dim/dim mice, whereas LPS caused a 20-fold increase in transcript in treated macrophages derived from WT or GR Then, MEF from GR dim/dim mice were assessed for their ability to produce PTX3 in response to GC. A series of 3 experiments were performed (Figure 9 Panel B). As expected, MEF from WT mice produced 8.4 ± 1.34ng/mL (p = 0.003 vs untreated), 30.1 ± 0.6ng/mL and 52.6 ± 3.8ng/mL (p = 0.002 vs TNFα) of PTX3, in response to Dex, TNFα and to the combined treatment respectively. PTX3 induction and superinduction by Dex corresponded to 28.0% and 174.6% of the response to TNFα (Figure 9 Panel B). In contrast, MEF from GR dim/dim mice did to not produce PTX3 in response to Dex (5.9 ± 1.3ng/mL) compared to 7.0 ± 0.1ng/mL for untreated cells. In GR dim/dim mice no significant superinduction of the response to TNFα by Dex was observed (Figure 9 Panel B). Overall these results indicate that in hematopoietic cells, GC-GR complex binding to NFκB and AP-1 transcription factors leads to inhibition of PTX3 gene expression, while in non-hematopoietic cells GC-GR complexes directly activate PTX3 transcription by GR binding to the PTX3 promoter. To definitely assess the importance of GC-GR complexes in the transcriptional activation of PTX3 gene, ChIP analysis was conducted in WI38 (n = 3) and HUVEC (n = 2) with RNA pol II and GR antibodies. In agreement with gene expression analysis, results obtained in WI38 (one representative experiment is shown in Figure 10 Panel A, upper part) and HUVEC (Supplemental Data Figure S5) showed that binding of RNA pol II to PTX3 promoter was induced upon stimulation (2h) with Dex (10 -6 M), TNFα (20ng/mL) and the combination of two stimuli. Furthermore, Dex, but not TNFα, stimulation was able to induce GR recruitment to the PTX3 promoter (Figure 10 Panel A, lower part), thus demonstrating that GC-GR complexes play a role in the transcriptional activation of PTX3 gene in WI38 and HUVEC. In contrast, ChIP analysis performed in hematopoietic cells (DC) (n = 2, one experiment shown) showed that the LPS-induced binding of RNA pol II to the PTX3 promoter was inhibited by Dex (Figure 10 
Panel B). Effect of GC on PTX3 levels in mice and humans
It was of interest to ascertain the in vivo effect of exogenous GC on PTX3 levels in mice. Figure  11 shows a typical experiment, of 3 performed, in which C57/BL6 mice following a 24h treatment with Dex (30mg/Kg) markedly showed increased circulating levels of PTX3 (53.7 ± 6.8ng/mL, n = 6, p < 0.05) compared to control animals (22.0 ± 4.4ng/mL, n = 6). Circulating levels of PTX3 were then measured in patients affected by Cushing's syndrome (hypercortisolism) and hypocortisolism in order to evaluate a regulatory effect of endogenous GC hormones on PTX3 in humans. As shown in Figure 12 Panel A, the PTX3 serum concentration in 18 normal donors was 2.6 ± 0.3ng/mL, similar to that observed in other studies (33, 38) . On the other hand, PTX3 levels were augmented in patients affected by Cushing's syndrome (6.0 ± 0.6ng/mL, n = 16, p = 0.00015 vs. control group) and significantly, decreased in patients affected by hypocortisolism (1.1 ± 0.1ng/mL, n = 9, p = 0.00051 vs. control group). In 7 normal subjects circulating levels of PTX3 were measured 24h after treatment with a low dose of Dex (1mg). PTX3 was found to be augmented after Dex administration from 2.2 ± 0.7ng/mL to 5.0 ± 1.6ng/mL, p = 0.0073 (Figure 12 Panel B) . When hystological analysis were conducted in skin of a patient affected by severe Cushing's syndrome, strong interstitial staining for PTX3 was observed in the derma (Figure 12 Panel C).
DISCUSSION
Glucocorticoid hormones (GC) have profound effects on innate and adaptive immune responses and are a major tool in the armamentarium of anti inflammatory/immunosuppressive agents (28) (29) (30) . In view also of the use of PTX3 as a novel marker of inflammation (3, (40) (41) (42) it was important to assess the effect of GC on this key component of humoral innate immunity. Unexpectedly, we found that GC have divergent effects on PTX3 production in hematopoietic (macrophages and DC) and non-hematopoietic (fibroblasts and EC) cells, with inhibition in the former and induction in the latter.
Cell context-dependent regulation was also observed when the PTX3 promoter was tested in a reporter gene assay with divergent regulation in macrophages (inhibition) and fibroblastic cells (induction). Inhibition and induction are both GR-mediated, as revealed by a specific antagonist (RU486), but ordered by different mechanisms of action.
GC receptor (GR) exerts regulatory activity through complex mechanisms: it functions as ligand-dependent transcription factor through direct (dimerization-dependent) DNA binding or it represses gene transcription through a protein-protein (dimerizationindependent) interference with the action of other signalling pathways (30, 39, 43, 44) . Here we report that GC-mediated downregulation of PTX3 in hematopoietic cells is independent of GR dimerization since LPSinduced PTX3 expression was efficiently downregulated in macrophages from GR dim/dim mice. On the other hand, PTX3 induction was observed in fibroblasts from WT mice but not GR dim/dim mice. GC exert many of anti-inflammatory actions by interfering with other signalling pathways and GR interactions with NFκB and AP-1 occur in GR dim/dim mice, in which GR-mediated gene activation is impaired (32, 45) . The human and murine PTX3 promoters have been both characterized and NFκB plays a pivotal role in PTX3 gene regulation (36, 37) . More recently, PTX3 has been shown to be regulated by the FUS/CHOP oncogene (46, 47) . Here we report that the human PTX3 promoter contains putative GR responsive elements, that in nonhematopoietic cells the PTX3 promoter is activated by GC and that the stimulation of PTX3 gene expression and production is dimerization-dependent. In contrast, GCmediated suppression of PTX3 expression in cells of hemopoietic origin is dimerizationindependent and likely mediated by interference with the NFκB pathway. Chromatin immunoprecipitation experiments confirmed the transcriptional activation of the PTX3 gene by Dex in non-hematopoietic (fibroblasts and endothelial cells), but not in myeloid cells. The results offer new unexpected vistas on cell context-dependent PTX3 gene regulation.
The finding that the effect of GC on PTX3 production is cell context dependent is hardly surprising. Data presented here establish that PTX3 production is subjected to regulatory constraints that differ according to cell type. The phenomenon of GC-mediated opposite cellspecific effects on the apoptotic pathway has been demonstrated by different authors. For instance, while GC mediate pro-apoptotic events in the majority of hematological cells, GCinduced anti-apoptotic signaling has been identified in cells of epithelial origin, and the underlying mechanisms have not been fully understood yet (48) . Moreover, cell type-specific opposite regulation of the same gene has been recently described for thyroid receptor (TR), a nuclear receptor highly homologous to GR, that has been shown to positively regulate type 1 iodothyronine deiodinase gene in COS-7 and HEK-293 cells, and suppress the same gene expression in the JEG-3 choriocarcinoma cell line. This negative regulation was demonstrated to require both TR-DNA binding and the presence of a JEG-3 specific transcription factor, not present in COS-7 or HEK-293 cells (49) .
GC are more than simple inhibitors of inflammation and immunity. Indeed GC have been shown to enhance the expression of scavenger receptors (e. g. MARCO, CD163) as well as complement components (e.g. C1q, C3, C5), TLR family members, SAA family proteins, Fibrinogen, the collectin MBL and surfactant proteins SP-A and SP-D (50) (51) (52) (53) (54) (55) (56) . Interestingly, PTX3 binds C1q and activates the classic pathway of complement activation and both are augmented by GC. SAA, MBL, Fibrinogen, SP-A and SP-D play key roles in the extracellular matrix, are components of the humoral arm of innate immunity produced by non-hematopoietic cells and share with PTX3 the property to be augmented by GC.
PTX3 is a prototypic long pentraxin structurally related to the short pentraxins CRP and SAP (3, 4, 6) . It was previously shown that induction of the acute phase proteins (e.g. SAA) is impaired in the liver of GR dim/dim mice (57). GC selectively induce regulate acute-phase and extracellular matrix proteins such as SAA family proteins, Fibrinogen, surfactant proteins SP-A and SP-D, but not CRP and SAP. In addition, GC oppositely regulate IL-6 (inhibition) and IL-10 (induction), key inducers of CRP/SAP and PTX3 (1,3) .
PTX3 binds TSG-6 and acts as a focal point in the assembly of hyaluronic acid rich extracellular matrices. PTX3 levels are augmented in humans after GC administration and are elevated in patients affected by Cushing's syndrome. Interestingly, PTX3 is found to localize in the derma of these patients. Patients with Cushing's syndrome have alterations in the extracellular matrix with loss of connective tissue, leading to fragility and atrophy of the skin, thinning of the stratum corneum and loss of subcutaneous fat. All this explains skin easy bruising after minimal trauma, the frequent presence of extensive ecchymoses and the formation of typical striae rubrae on the stretched, fragile skin. It remains to be ascertained whether unbalanced production of PTX3 by fibroblasts and endothelial cells induced by GC plays a role in these manifestations of Cushing's syndrome.
The results presented here indicate the regulation of PTX3 by GC is cell contextdependent, with inhibition in hematopoietic cells (macrophages and DC) and induction in nonhematopoietic cells (fibroblasts and endothelial cells). The divergent effects of GC on PTX3 production in diverse cellular contexts is likely to reflect the diverse roles of this multifunctional protein in innate immunity, inflammation, and in the assembly of the extracellular matrix. experiments of several performed (WI38 n = 3, HUVEC n = 2, DC n = 2) and mean of a triplicate. FIGURE 11: Effect of GC on PTX3 blood levels in mice. The figure presents a typical in vivo experiment of 3 performed. C57/BL6 mice (n = 6 per group) were given Dex (30mg/Kg) i. p. or vehicle 24h before sacrifice. Results are mean ± SD. * = p < 0.05 vs. control group. FIGURE 12: Regulation of peripheral blood PTX3 levels by GC in humans. Panel A, PTX3 levels in Cushing's syndrome patients (n = 16), patients affected by hypocortisolism (n = 9) and healthy donors (n = 18). In Panel B PTX3 levels in 7 normal subjects treated with Dex (1mg) before obtaining peripheral blood (overnight treatment). Panel C, hystological analysis of PTX3 localization in a skin of a patient affected by Cushing's syndrome and healthy donor are shown. PTX3 staining is performed as described in Experimental Procedures. PTX3 = brown; Bar = 50µm.
